The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Axsome Therapeutics P/E ratio is -0.01. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Axsome Therapeutics’s P/E ratio
What is Axsome Therapeutics P/E Ratio?
Axsome Therapeutics’ P/E ratio is -0.01, which represents a 99.95% increase over the same period last year. their average P/E ratio is -7.71 and their 5-year average is -12.71.
What is Axsome Therapeutics Net EPS?
Axsome Therapeutics’ net earnings for the most recent quarter were -4274.0$, which represents a 140956.11% decrease from the same period last year.
Who are Axsome Therapeutics Competitors?
Based on Jika.io AI model, Alector, Atea Pharmaceuticals, ChemoCentryx, Lexicon Pharmaceuticals, uniQure N.V., Xenon Pharmaceuticals, Y-mAbs Therapeutics, Zentalis Pharmaceuticals are considered to be Axsome Therapeutics’s competitors because the companies operate within the same industry as Axsome Therapeutics and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Axsome Therapeutics.
Who is Axsome Therapeutics’s Biggest competitor?
Axsome Therapeutics’ biggest competitor is Alector, based on the Jika.io AI model. it has a similar market capitalization to Axsome Therapeutics within the industry, it dominates a similar share of the market as Axsome Therapeutics, and it provides and markets very similar services.
What industry is Axsome Therapeutics in?
Axsome Therapeutics is part of the biotechnology and healthcare industry.
Axsome Therapeutics vs Alector
Market Cap: Axsome Therapeutics’s Market Cap of 1663167360 is higher than Alector Market Cap of 951698944.
Average Volume: Axsome Therapeutics’s Average Volume of 1.662M is lower than Alector Average Volume of 674365.0.
Beta: Axsome Therapeutics’s Beta of 2.49 is higher than Alector Beta of 1.37.
Revenue: Axsome Therapeutics’s Revenue of 0.0 is lower than Alector Revenue of 207.085M.
Net Income: Axsome Therapeutics’s Net Income of -130.403B is lower than Alector Net Income of -36.329M.
Gross Profit: Axsome Therapeutics’s Gross Profit of 0.0 is lower than Alector Gross Profit of 0.0.
Ebitda: Axsome Therapeutics’s Ebitda of -124.706B is lower than Alector Ebitda of -28.014M.
P/E Ratio: Axsome Therapeutics’s P/E Ratio of -0.01 is lower than Alector P/E Ratio of -32.98.
P/B Ratio: Axsome Therapeutics’s P/B Ratio of 111.44 is lower than Alector P/B Ratio of 3.55.
P/FCF Ratio: Axsome Therapeutics’s P/FCF Ratio of -14.39 is lower than Alector P/FCF Ratio of 1.96.
ROE: Axsome Therapeutics’s ROE of -3613.16 is higher than Alector ROE of -0.11.
ROA: Axsome Therapeutics’s ROA of -1473.68 is higher than Alector ROA of -0.03.
Return On Capital Employed: Axsome Therapeutics’s Return On Capital Employed of -2.11 is higher than Alector Return On Capital Employed of -0.04.
Assets (Total): Axsome Therapeutics’s Assets (Total) of 87.785M is higher than Alector Assets (Total) of 814.658M.
Debt (Total): Axsome Therapeutics’s Debt (Total) of 620675.0 is higher than Alector Debt (Total) of 47.601M.
Shareholders Equity: Axsome Therapeutics’s Shareholders Equity of 15.63M is lower than Alector Shareholders Equity of 300.724M.
Axsome Therapeutics vs Atea Pharmaceuticals
Market Cap: Axsome Therapeutics’s Market Cap of 1663167360 is higher than Atea Pharmaceuticals Market Cap of 588631232.
Average Volume: Axsome Therapeutics’s Average Volume of 1.662M is lower than Atea Pharmaceuticals Average Volume of 742475.0.
Beta: Axsome Therapeutics’s Beta of 2.49 is higher than Atea Pharmaceuticals Beta of 0.0.
Revenue: Axsome Therapeutics’s Revenue of 0.0 is lower than Atea Pharmaceuticals Revenue of 351.367M.
Net Income: Axsome Therapeutics’s Net Income of -130.403B is lower than Atea Pharmaceuticals Net Income of 121.19M.
Gross Profit: Axsome Therapeutics’s Gross Profit of 0.0 is lower than Atea Pharmaceuticals Gross Profit of 0.0.
Ebitda: Axsome Therapeutics’s Ebitda of -124.706B is lower than Atea Pharmaceuticals Ebitda of 138.619M.
P/E Ratio: Axsome Therapeutics’s P/E Ratio of -0.01 is lower than Atea Pharmaceuticals P/E Ratio of 13.34.
P/B Ratio: Axsome Therapeutics’s P/B Ratio of 111.44 is higher than Atea Pharmaceuticals P/B Ratio of 0.86.
P/FCF Ratio: Axsome Therapeutics’s P/FCF Ratio of -14.39 is lower than Atea Pharmaceuticals P/FCF Ratio of -4.55.
ROE: Axsome Therapeutics’s ROE of -3613.16 is lower than Atea Pharmaceuticals ROE of 0.08.
ROA: Axsome Therapeutics’s ROA of -1473.68 is lower than Atea Pharmaceuticals ROA of 0.07.
Return On Capital Employed: Axsome Therapeutics’s Return On Capital Employed of -2.11 is lower than Atea Pharmaceuticals Return On Capital Employed of 0.1.
Assets (Total): Axsome Therapeutics’s Assets (Total) of 87.785M is higher than Atea Pharmaceuticals Assets (Total) of 772.892M.
Debt (Total): Axsome Therapeutics’s Debt (Total) of 620675.0 is higher than Atea Pharmaceuticals Debt (Total) of 0.0.
Shareholders Equity: Axsome Therapeutics’s Shareholders Equity of 15.63M is lower than Atea Pharmaceuticals Shareholders Equity of 710.077M.
Axsome Therapeutics vs ChemoCentryx
Market Cap: Axsome Therapeutics’s Market Cap of 1663167360 is lower than ChemoCentryx Market Cap of 1803328768.
Average Volume: Axsome Therapeutics’s Average Volume of 1.662M is higher than ChemoCentryx Average Volume of 1.456M.
Beta: Axsome Therapeutics’s Beta of 2.49 is higher than ChemoCentryx Beta of 1.94.
Revenue: Axsome Therapeutics’s Revenue of 0.0 is lower than ChemoCentryx Revenue of 32.224M.
Net Income: Axsome Therapeutics’s Net Income of -130.403B is lower than ChemoCentryx Net Income of -131.755M.
Gross Profit: Axsome Therapeutics’s Gross Profit of 0.0 is lower than ChemoCentryx Gross Profit of 31.922M.
Ebitda: Axsome Therapeutics’s Ebitda of -124.706B is lower than ChemoCentryx Ebitda of -131.311M.
P/E Ratio: Axsome Therapeutics’s P/E Ratio of -0.01 is lower than ChemoCentryx P/E Ratio of -12.76.
P/B Ratio: Axsome Therapeutics’s P/B Ratio of 111.44 is lower than ChemoCentryx P/B Ratio of 6.94.
P/FCF Ratio: Axsome Therapeutics’s P/FCF Ratio of -14.39 is lower than ChemoCentryx P/FCF Ratio of -33.48.
ROE: Axsome Therapeutics’s ROE of -3613.16 is higher than ChemoCentryx ROE of -0.47.
ROA: Axsome Therapeutics’s ROA of -1473.68 is higher than ChemoCentryx ROA of -0.32.
Return On Capital Employed: Axsome Therapeutics’s Return On Capital Employed of -2.11 is higher than ChemoCentryx Return On Capital Employed of -0.37.
Assets (Total): Axsome Therapeutics’s Assets (Total) of 87.785M is higher than ChemoCentryx Assets (Total) of 425.652M.
Debt (Total): Axsome Therapeutics’s Debt (Total) of 620675.0 is higher than ChemoCentryx Debt (Total) of 4.715M.
Shareholders Equity: Axsome Therapeutics’s Shareholders Equity of 15.63M is lower than ChemoCentryx Shareholders Equity of 286.12M.
Axsome Therapeutics vs Lexicon Pharmaceuticals
Market Cap: Axsome Therapeutics’s Market Cap of 1663167360 is higher than Lexicon Pharmaceuticals Market Cap of 393432224.
Average Volume: Axsome Therapeutics’s Average Volume of 1.662M is higher than Lexicon Pharmaceuticals Average Volume of 1.148M.
Beta: Axsome Therapeutics’s Beta of 2.49 is higher than Lexicon Pharmaceuticals Beta of 1.53.
Revenue: Axsome Therapeutics’s Revenue of 0.0 is lower than Lexicon Pharmaceuticals Revenue of 298000.0.
Net Income: Axsome Therapeutics’s Net Income of -130.403B is lower than Lexicon Pharmaceuticals Net Income of -87.758M.
Gross Profit: Axsome Therapeutics’s Gross Profit of 0.0 is lower than Lexicon Pharmaceuticals Gross Profit of 298000.0.
Ebitda: Axsome Therapeutics’s Ebitda of -124.706B is lower than Lexicon Pharmaceuticals Ebitda of -86.956M.
P/E Ratio: Axsome Therapeutics’s P/E Ratio of -0.01 is lower than Lexicon Pharmaceuticals P/E Ratio of -4.35.
P/B Ratio: Axsome Therapeutics’s P/B Ratio of 111.44 is lower than Lexicon Pharmaceuticals P/B Ratio of 4.23.
P/FCF Ratio: Axsome Therapeutics’s P/FCF Ratio of -14.39 is lower than Lexicon Pharmaceuticals P/FCF Ratio of -6.16.
ROE: Axsome Therapeutics’s ROE of -3613.16 is lower than Lexicon Pharmaceuticals ROE of 0.32.
ROA: Axsome Therapeutics’s ROA of -1473.68 is higher than Lexicon Pharmaceuticals ROA of -0.66.
Return On Capital Employed: Axsome Therapeutics’s Return On Capital Employed of -2.11 is higher than Lexicon Pharmaceuticals Return On Capital Employed of -0.76.
Assets (Total): Axsome Therapeutics’s Assets (Total) of 87.785M is higher than Lexicon Pharmaceuticals Assets (Total) of 136.909M.
Debt (Total): Axsome Therapeutics’s Debt (Total) of 620675.0 is higher than Lexicon Pharmaceuticals Debt (Total) of 0.0.
Shareholders Equity: Axsome Therapeutics’s Shareholders Equity of 15.63M is higher than Lexicon Pharmaceuticals Shareholders Equity of -1.488B.
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, is engaged in the development of novel therapies for central nervous system disorders in the United States. the company’s product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders, and is in Phase III clinical trial for Alzheimer’s disease agitation, and has completed Phase II clinical trial for smoking cessation. it also develops AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic and investigational medicine, which has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trials for the treatment of narcolepsy; and AXS-14, a novel, oral and investigational medicine, which is in Phase III trials for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for the evaluation of AXS-05 in smoking cessation. the company was established in 2012 and is based in New York, New York.